Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

This year, researchers Megan Shen, PhD, and Mary L. “Nora” Disis, MD, of Fred Hutch Cancer Center and UW Medicine ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." ...

University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

That means an ovarian cancer patient could receive an intravenous injection and have her tumor stop growing following one 30-minute, non-invasive magnetic field session.

Black and American Indian patients are less likely to have elevated CA-125 levels compared with White patients.

A clinician nudge at the time of a suspected ovarian cancer diagnosis improved gynecologic oncology referral rates by 20 percentage points. A randomized controlled trial of this strategy is planned.